Table 1.
Patient characteristics
| Dormant, n (%) | Resistant, n (%) | Total, n | p valuea | |
|---|---|---|---|---|
| Total no. of patients | 42 | 20 | 62 | |
| Total no. of samples | 111 | 56 | 167 | |
| Age at diagnosis | ||||
| Mean | 75 | 72 | ||
| Range | 53–87 | 56–89 | ||
| Tumour grade | 0.39 | |||
| 1 | 6 (14.3) | 1 (5.0) | 7 | |
| 2 | 27 (64.3) | 10 (50.0) | 37 | |
| 3 | 8 (19.0) | 6 (30.0) | 14 | |
| NA | 1 (2.4) | 3 (15.0) | 4 | |
| Tumour size | 0.71 | |||
| T1 | 5 (11.9) | 4 (20.0) | 9 | |
| T2 | 19 (45.2) | 9 (45.0) | 28 | |
| T3 | 2 (4.8) | 2 (10.0) | 4 | |
| T4 | 11 (26.2) | 4 (20.0) | 15 | |
| NA | 5 (11.9) | 1 (5.0) | 6 | |
| Nodal status | 0.36 | |||
| N0 | 27 (64.3) | 11 (55.0) | 38 | |
| N1 | 8 (19.0) | 7 (35.0) | 15 | |
| N2 | 1 (2.4) | 1 (5.0) | 2 | |
| N3 | 1 (2.4) | 0 | 1 | |
| NX | 1 (2.4) | 0 | 1 | |
| NA | 4 (9.5) | 1 (5.0) | 5 | |
| Metastasis status | 1.00 | |||
| M0 | 34 (80.9) | 18 (90.0) | 56 | |
| M1 | 2 (4.8) | 0 | 2 | |
| MX | 1 (2.4) | 1 (5.0) | 2 | |
| NA | 5 (11.9) | 1 (5.0) | 6 | |
| ER score (Allred) | 0.18 | |||
| 6 | 1 (2.4) | 0 | 1 | |
| 7 | 6 (14.3) | 6 (30.0) | 12 | |
| 8 | 35 (83.3) | 14 (70.0) | 49 | |
| HER status | 0.69 | |||
| Negative | 35 (83.3) | 12 (60.0) | 47 | |
| Positive | 6 (14.3) | 3 (15.0) | 9 | |
| NA | 1 (2.4) | 5 (25.0) | 6 | |
| Histological type | 0.73 | |||
| IDC (no special type) | 18 (42.9) | 6 (30) | 24 | |
| ILC | 8 (19.0) | 4 (20) | 12 | |
| Mucinous | 1 (2.4) | 0 | 1 | |
| NA | 15 (35.7) | 10 (50) | 25 | |
| Molecular subtypeb | 1.00 | |||
| Luminal A | 21 (50.0) | 9 (45.0) | 30 | |
| Luminal B | 20 (47.6) | 9 (45.0) | 29 | |
| HER2 enriched | 0 | 1 (5.0) | 1 | |
| Basal-like | 0 | 0 | 0 | |
| Normal-like | 0 | 0 | 0 | |
| NA | 1 (2.4) | 1 (5.0) | 2 | |
ER oestrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NA not available
aFisher exact test (p < 0.05, two-tailed)
bAt diagnosis by PAM50 (genefu)